<DOC>
	<DOCNO>NCT00877890</DOCNO>
	<brief_summary>This study compare effect commercially manufacture exenatide weekly exenatide BID subject whose type 2 diabetes manage diet exercise alone oral antidiabetic medication . The study examine glycemic control ( measure HbA1C ) , safety , tolerability .</brief_summary>
	<brief_title>A Study Evaluate Glycemic Effects , Safety , Tolerability Exenatide Once Weekly Subjects With Type 2 Diabetes Mellitus ( DURATION-5 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Has diagnose type 2 diabetes mellitus Has hemoglobinspecific A1c fraction ( HbA1c ) 7.1 % 11.0 % , inclusive , screen Has body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive , screening Has treat diet exercise alone combination stable regimen metformin ( MET ) , sulfonylurea ( SU ) , thiazolidinedione ( TZD ) , combination metformin SU , combination metformin TZD , combination SU TZD minimum 2 month prior screen Either treat stable treatment regimen follow medication minimum 2 month prior screen : Hormone replacement therapy ( female subject ) Oral contraceptive ( female subject ) Antihypertensive agent Lipidlowering agent Thyroid replacement therapy Antidepressant agent Drugs know affect body weight , include prescription medication ( e.g . orlistat [ XENICAL® ] , sibutramine [ MERIDIA® ] , topiramate [ TOPAMAX® ] ) counter antiobesity agent Has ever expose exenatide ( exenatide weekly [ exenatide LAR ] , exenatide BID , BYETTA , formulation ) glucagonlike peptide1 ( GLP1 ) analog Has receive investigational drug within one month ( five halflives investigational drug , whichever great ) screening Has treat , currently treat , expect require undergo treatment follow treatment exclude medication : Any dipeptidyl peptidase 4 ( DPP4 ) inhibitor within 3 month prior screen Alpha glucosidase inhibitor , meglitinide , nateglinide , pramlintide ( SYMLIN® ) within 30 day screen Insulin within 2 week screen 1 week within 3 month screen Systemic corticosteroid oral , intravenous , intramuscular route ; potent , inhale , intrapulmonary ( include ADVAIR® ) steroid know high rate systemic absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>Bydureon</keyword>
</DOC>